Cannabinoid Type 1 Receptor (CB1) Ligands with Therapeutic Potential for Withdrawal Syndrome in Chemical Dependents ofCannabis sativa

Autor:	Bianca L. B. Marino, Hueldem R. C. Teixeira, Jaderson Vieira Ferreira, Carlos Henrique Tomich de Paula da Silva, Maiara de Fátima de Brito Brito, Cleydson B. R. Santos, Kessia P. A. Sousa, Gisele A. Chaves, Lucilene R. de Souza, Lorane Izabel da Silva Hage-Melim
Rok vydání:	2017
Předmět:	0301 basic medicine Drug Cell Membrane Permeability Cannabinoid receptor media_common.quotation_subject medicine.medical_treatment Pharmacology Ligands Cannabis sativa Biochemistry Receptor Cannabinoid CB2 Mice 03 medical and health sciences 0302 clinical medicine Receptor Cannabinoid CB1 Drug Discovery Animals Humans Medicine General Pharmacology Toxicology and Pharmaceutics Receptor Cannabis media_common Virtual screening business.industry Ligand Organic Chemistry food and beverages Resorcinols Substance Withdrawal Syndrome 030104 developmental biology Blood-Brain Barrier Drug Design Molecular Medicine Cannabinoid Caco-2 Cells Withdrawal syndrome business 030217 neurology & neurosurgery Half-Life
Zdroj:	ChemMedChem. 12:1408-1416
ISSN:	1860-7179
Popis:	Cannabis sativa withdrawal syndrome is characterized mainly by psychological symptoms. By using computational tools, the aim of this study was to propose drug candidates for treating withdrawal syndrome based on the natural ligands of the cannabinoid type 1 receptor (CB1). One compound in particular, 2-n-butyl-5-n-pentylbenzene-1,3-diol (ZINC1730183, also known as stemphol), showed positive predictions as a human CB1 ligand and for facile synthetic accessibility. Therefore, ZINC1730183 is a favorable candidate scaffold for further research into pharmacotherapeutic alternatives to treat C. sativa withdrawal syndrome.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b0f83ecd4e511927692c9446be5daa5 https://doi.org/10.1002/cmdc.201700129 Zobrazit plný text záznamu Plný text